Victory Capital Management Inc. Increases Position in Perrigo Company plc (NYSE:PRGO)

Victory Capital Management Inc. lifted its position in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 3.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,107,135 shares of the company's stock after acquiring an additional 37,758 shares during the quarter. Victory Capital Management Inc. owned approximately 0.82% of Perrigo worth $35,628,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC lifted its holdings in Perrigo by 4.1% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 9,627 shares of the company's stock worth $310,000 after purchasing an additional 380 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Perrigo by 34.5% in the 4th quarter. Blue Trust Inc. now owns 1,556 shares of the company's stock valued at $50,000 after acquiring an additional 399 shares in the last quarter. Xponance Inc. raised its holdings in shares of Perrigo by 2.1% in the 4th quarter. Xponance Inc. now owns 20,153 shares of the company's stock valued at $649,000 after acquiring an additional 410 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Perrigo by 25.6% in the 4th quarter. Signaturefd LLC now owns 2,240 shares of the company's stock valued at $72,000 after acquiring an additional 457 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in shares of Perrigo by 39.5% in the 3rd quarter. Fifth Third Bancorp now owns 1,714 shares of the company's stock valued at $55,000 after acquiring an additional 485 shares in the last quarter. Institutional investors own 95.91% of the company's stock.

Perrigo Stock Down 9.8 %

Shares of PRGO traded down $3.28 on Tuesday, reaching $30.15. The stock had a trading volume of 3,897,367 shares, compared to its average volume of 1,803,637. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of -311.70 and a beta of 0.63. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.07 and a current ratio of 1.79. The company has a 50-day simple moving average of $30.62 and a 200-day simple moving average of $30.93. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28.

Perrigo (NYSE:PRGO - Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The firm's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. Sell-side analysts predict that Perrigo Company plc will post 2.55 EPS for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Friday, May 31st will be paid a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a yield of 3.66%. The ex-dividend date is Friday, May 31st. Perrigo's payout ratio is -1,100.00%.

Insider Buying and Selling at Perrigo

In related news, CEO Patrick Lockwood-Taylor acquired 9,500 shares of the stock in a transaction on Thursday, February 29th. The stock was acquired at an average price of $26.54 per share, for a total transaction of $252,130.00. Following the completion of the purchase, the chief executive officer now owns 20,500 shares of the company's stock, valued at $544,070. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Alison Ives acquired 2,490 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the acquisition, the executive vice president now directly owns 16,122 shares of the company's stock, valued at approximately $439,485.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick Lockwood-Taylor acquired 9,500 shares of the business's stock in a transaction that occurred on Thursday, February 29th. The stock was purchased at an average cost of $26.54 per share, with a total value of $252,130.00. Following the acquisition, the chief executive officer now directly owns 20,500 shares of the company's stock, valued at $544,070. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 17,990 shares of company stock worth $475,227. 0.40% of the stock is owned by insiders.

Analyst Ratings Changes

PRGO has been the topic of a number of research reports. JPMorgan Chase & Co. decreased their price objective on Perrigo from $48.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, February 28th. Canaccord Genuity Group reissued a "buy" rating and set a $42.00 price objective on shares of Perrigo in a report on Friday, April 12th. Piper Sandler raised their price target on Perrigo from $35.00 to $39.00 and gave the stock an "overweight" rating in a research report on Monday, April 8th. Finally, StockNews.com upgraded Perrigo from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.